{"transactions":[{"id":714858,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested in substantially equal monthly installments over the 11 months following June 23, 2025. The final unvested portion vested on June 15, 2026, the date of the Issuer's 2026 annual meeting of stockholders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2035-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714857,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":2.49,"value":39840.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":714856,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":5,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:44:44.000Z","date":"2026-07-01","kind":"exercise","planned":false,"acquired":true,"shares":16000,"price":1.03,"value":16480.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a cashless stock option exercise by Kristina Burow. The net proceeds of such exercise were remitted to ARCH Venture Fund IX, L.P. (ARCH IX), ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage), and ARCH Venture Fund X, L.P. (AVF X Overage LP). The stock option was granted to Kristina Burow in connection with her service on the board of directors of the Issuer."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001012975-26-000622","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000101297526000622/form4.xml","form_type":"4"}},{"id":727902,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:18:45.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":1250000,"price":16,"value":20000000.0,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":15042035,"source":{"system":"sec-edgar","filing":"0001012975-26-000564","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000564/form4.xml","form_type":"4"}},{"id":730778,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":2306401,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3673635},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730777,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":1204000,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1917731},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730776,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":5148587,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8200669},"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":730775,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":1,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":3,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:39:44.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":13792035,"ownership":{"direct":false,"nature":"By: ARCH Venture Fund XIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B Preferred Stock and Series B-1 Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into the number of shares shown in Column 7 on a 1.5928 for 1 basis upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Mr. Berns serves on the board of directors of the Issuer. Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":13792035,"source":{"system":"sec-edgar","filing":"0001193125-26-277985","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000119312526277985/ownership.xml","form_type":"4"}},{"id":739442,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (option to buy)","published_at":"2026-06-12T20:46:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":6209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":6209,"derivative":{"exercise_price":8.22,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":6209},"source":{"system":"sec-edgar","filing":"0001219039-26-000002","document":"form4-06122026_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121903926000002/form4-06122026_080610.xml","form_type":"4"}},{"id":739441,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-12T20:46:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":13656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."}],"balance_after":13656,"derivative":{"underlying":"Common Stock","underlying_shares":13656},"source":{"system":"sec-edgar","filing":"0001219039-26-000002","document":"form4-06122026_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121903926000002/form4-06122026_080610.xml","form_type":"4"}},{"id":739440,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-12T20:46:14.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":false,"shares":14083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14083},"source":{"system":"sec-edgar","filing":"0001219039-26-000002","document":"form4-06122026_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121903926000002/form4-06122026_080610.xml","form_type":"4"}},{"id":739439,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T20:46:14.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":true,"shares":14083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."}],"balance_after":39374,"source":{"system":"sec-edgar","filing":"0001219039-26-000002","document":"form4-06122026_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121903926000002/form4-06122026_080610.xml","form_type":"4"}},{"id":794166,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2681265,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2681265},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794165,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":2513686,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2513686},"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794164,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"purchase","planned":false,"acquired":true,"shares":1100000,"price":18,"value":19800000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6294951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794163,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2681265,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":5194951,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":794162,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T22:02:53.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":2513686,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 and Series B Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2513686,"source":{"system":"sec-edgar","filing":"0001193125-26-204458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204458/ownership.xml","form_type":"4"}},{"id":853893,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":1,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":2,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":3,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20890,"kind":"person","name":"BERNS PAUL L","position":8,"cik":"0001202769","reported_name":"BERNS PAUL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":9,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-09T20:34:54.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":488090,"price":25.61,"value":12499984.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP.  Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1426528,"source":{"system":"sec-edgar","filing":"0001012975-26-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016082/000101297526000234/form4.xml","form_type":"4"}},{"id":914197,"issuer":{"id":3619,"kind":"organization","name":"Twist Bioscience Corp","symbol":"TWST"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-09T22:34:35.000Z","date":"2026-02-05","kind":"grant","planned":false,"acquired":true,"shares":5095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date."}],"balance_after":27571,"source":{"system":"sec-edgar","filing":"0001214659-26-001352","document":"marketforms-72065.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121465926001352/marketforms-72065.xml","form_type":"4"}},{"id":999081,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8313680,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P. (\"ARCH Venture Fund XIII\").  ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII.  AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares.  Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":999080,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T18:34:16.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18503128,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"date","element":"transactionDate","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001012975-25-000791","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000101297525000791/form4.xml","form_type":"4"}},{"id":1012114,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-29T23:21:13.000Z","date":"2025-10-27","kind":"purchase","planned":false,"acquired":true,"shares":1915700,"price":2.61,"value":4999977.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6046907,"source":{"system":"sec-edgar","filing":"0001012975-25-000680","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000101297525000680/form4.xml","form_type":"4"}},{"id":1077712,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73810,"kind":"organization","name":"ARCH Venture Partners X, L.P.","position":2,"cik":"0001782583","reported_name":"ARCH Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":3,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73809,"kind":"organization","name":"ARCH Venture Fund X, L.P.","position":4,"cik":"0001757011","reported_name":"ARCH Venture Fund X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":5,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":6,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":7,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-01T23:18:42.000Z","date":"2025-08-01","kind":"purchase","planned":false,"acquired":true,"shares":3030300,"price":3.3,"value":9999990.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":6230300,"source":{"system":"sec-edgar","filing":"0001062993-25-013460","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299325013460/form4.xml","form_type":"4"}},{"id":1111262,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (option to buy)","published_at":"2025-06-13T20:18:44.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":6516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 12, 2025, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":6516,"derivative":{"exercise_price":7.19,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":6516},"source":{"system":"sec-edgar","filing":"0001562180-25-004804","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218025004804/primarydocument.xml","form_type":"4"}},{"id":1111261,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-13T20:18:44.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":14083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs become fully vested on June 12, 2026 or the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs become fully vested on June 12, 2026 or the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."}],"balance_after":14083,"derivative":{"underlying":"Common Stock","underlying_shares":14083},"source":{"system":"sec-edgar","filing":"0001562180-25-004804","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218025004804/primarydocument.xml","form_type":"4"}},{"id":1111260,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-13T20:18:44.000Z","date":"2025-06-11","kind":"exercise","planned":false,"acquired":false,"shares":11364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs became fully vested on June 11, 2025, the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs became fully vested on June 11, 2025, the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11364},"source":{"system":"sec-edgar","filing":"0001562180-25-004804","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218025004804/primarydocument.xml","form_type":"4"}},{"id":1111259,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:18:44.000Z","date":"2025-06-11","kind":"exercise","planned":false,"acquired":true,"shares":11364,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."}],"balance_after":25291,"source":{"system":"sec-edgar","filing":"0001562180-25-004804","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218025004804/primarydocument.xml","form_type":"4"}},{"id":1278537,"issuer":{"id":3619,"kind":"organization","name":"Twist Bioscience Corp","symbol":"TWST"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T22:16:49.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":4472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date."}],"balance_after":22476,"source":{"system":"sec-edgar","filing":"0001214659-25-002256","document":"marketforms-68034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121465925002256/marketforms-68034.xml","form_type":"4"}},{"id":1287653,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287652,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383731},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287651,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":2678571,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1139951},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287650,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":15000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6383730},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287649,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":false,"shares":19933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8483268},"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287648,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":789998,"price":18,"value":14219964.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":8313680,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287647,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"purchase","planned":false,"acquired":true,"shares":1432224,"price":18,"value":25780032.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":18503128,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287646,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":7523682,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund XIII, L.P.(\"ARCH Venture Fund XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XIII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from footnote 3)  Each of Kristina Burow and Paul Berns has filed a separate Form 4."}],"balance_after":7523682,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1287645,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":2,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35731,"kind":"person","name":"ARCH Venture Fund XIII, L.P.","position":4,"cik":"0002006772","reported_name":"ARCH Venture Fund XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35730,"kind":"person","name":"ARCH Venture Partners XIII, L.P.","position":5,"cik":"0002016083","reported_name":"ARCH Venture Partners XIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35729,"kind":"person","name":"ARCH Venture Partners XIII, LLC","position":6,"cik":"0002016082","reported_name":"ARCH Venture Partners XIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":7,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":9,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-03T19:01:33.000Z","date":"2025-02-03","kind":"exercise","planned":false,"acquired":true,"shares":16006949,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-for-2.349723.  The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund XII, L.P (\"ARCH Venture Fund XII\").  ARCH Venture Partners XII, L.P. (\"AVP XII LP\"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  ARCH Venture Partners XII, LLC (\"AVP XII LLC\"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII.  AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein.  As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the \"AVP XII Committee Members\") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares.  Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":17070904,"source":{"system":"sec-edgar","filing":"0000950170-25-012579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025012579/ownership.xml","form_type":"4"}},{"id":1478717,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (option to buy)","published_at":"2024-06-14T20:21:40.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 13, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":15996,"derivative":{"exercise_price":5.94,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15996},"source":{"system":"sec-edgar","filing":"0001562180-24-005066","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218024005066/primarydocument.xml","form_type":"4"}},{"id":1478716,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-06-14T20:21:40.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":11364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs become fully vested on June 13, 2025 or the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs become fully vested on June 13, 2025 or the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."}],"balance_after":11364,"derivative":{"underlying":"Common Stock","underlying_shares":11364},"source":{"system":"sec-edgar","filing":"0001562180-24-005066","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218024005066/primarydocument.xml","form_type":"4"}},{"id":1478715,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-06-14T20:21:40.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":false,"shares":7777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs became fully vested on June 12, 2024, the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs became fully vested on June 12, 2024, the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7777},"source":{"system":"sec-edgar","filing":"0001562180-24-005066","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218024005066/primarydocument.xml","form_type":"4"}},{"id":1478714,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T20:21:40.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":true,"shares":7777,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."}],"balance_after":13927,"source":{"system":"sec-edgar","filing":"0001562180-24-005066","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218024005066/primarydocument.xml","form_type":"4"}},{"id":1485283,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":11924138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392738},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485282,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2336000},"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1485281,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":5,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":6,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":7,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T23:46:32.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":3728738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3728738,"source":{"system":"sec-edgar","filing":"0000950170-24-071543","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017024071543/ownership.xml","form_type":"4"}},{"id":1547695,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":366301,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":366301},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547694,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":201465,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":201465},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547693,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":164835,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":164835},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547692,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":227920,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":227920},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547691,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":454212,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":454212},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547690,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":586080,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":586080},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547689,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":424908,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":424908},"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547688,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":16,"value":2133328.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering."}],"balance_after":1181766,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547687,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":66667,"price":16,"value":1066672.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Reflects shares purchased by ARCH IX in the Issuer's initial public offering."}],"balance_after":683759,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547686,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":1048433,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any."}],"balance_after":1048433,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547685,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":787545,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage).  ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":828570,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1547684,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":3,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T20:30:41.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":589743,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any."}],"balance_after":617092,"source":{"system":"sec-edgar","filing":"0000950170-24-041842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000095017024041842/ownership.xml","form_type":"4"}},{"id":1634284,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73810,"kind":"organization","name":"ARCH Venture Partners X, L.P.","position":2,"cik":"0001782583","reported_name":"ARCH Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32126,"kind":"organization","name":"ARCH Venture Partners X Overage, L.P.","position":3,"cik":"0001768905","reported_name":"ARCH Venture Partners X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73809,"kind":"organization","name":"ARCH Venture Fund X, L.P.","position":4,"cik":"0001757011","reported_name":"ARCH Venture Fund X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32123,"kind":"organization","name":"ARCH Venture Fund X Overage, L.P.","position":5,"cik":"0001757017","reported_name":"ARCH Venture Fund X Overage, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":6,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":7,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":8,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T22:37:44.000Z","date":"2024-02-15","kind":"purchase","planned":false,"acquired":true,"shares":3200000,"price":6.25,"value":20000000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (\"ARCH XII\"). ARCH Venture Partners XII, L.P. (\"AVP XII LP\") is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (\"AVP XII LLC\") is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP XII LLC (the \"AVP XII LLC Committee Members\"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3200000,"source":{"system":"sec-edgar","filing":"0001062993-24-003738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000106299324003738/form4.xml","form_type":"4"}},{"id":1648965,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage).  ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1648964,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":727272,"price":5.5,"value":3999996.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X).  ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein."}],"balance_after":12446022,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1648963,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":2,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32075,"kind":"person","name":"Burow Kristina","position":3,"cik":"0001569248","reported_name":"Burow Kristina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":4,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-12T22:43:56.000Z","date":"2024-02-08","kind":"purchase","planned":false,"acquired":true,"shares":363637,"price":5.5,"value":2000003.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX).  ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein."}],"balance_after":10667387,"source":{"system":"sec-edgar","filing":"0001062993-24-002841","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229592/000106299324002841/form4.xml","form_type":"4"}},{"id":1651372,"issuer":{"id":3619,"kind":"organization","name":"Twist Bioscience Corp","symbol":"TWST"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-09T21:10:27.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":5815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date."}],"balance_after":18004,"source":{"system":"sec-edgar","filing":"0001214659-24-002246","document":"marketforms-64638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121465924002246/marketforms-64638.xml","form_type":"4"}},{"id":1714601,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":1176593,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2321566,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1714600,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":7,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T00:53:13.000Z","date":"2023-12-08","kind":"other","planned":false,"acquired":true,"shares":703061,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer.  Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to  former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones.  Shares were received without any action by Reporting Persons.  No additional consideration was paid for the shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1387228,"source":{"system":"sec-edgar","filing":"0001062993-23-022481","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323022481/form4.xml","form_type":"4"}},{"id":1740990,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-14","kind":"purchase","planned":false,"acquired":true,"shares":3357,"price":11.98,"value":40216.86,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4131207,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1740989,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-15T23:54:20.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":31653,"price":11.75,"value":371922.75,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4127850,"source":{"system":"sec-edgar","filing":"0001062993-23-020933","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020933/form4.xml","form_type":"4"}},{"id":1744258,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":5431,"price":11.75,"value":63814.25,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4096197,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744257,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":11844,"price":11.37,"value":134666.28,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4090766,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744256,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-09","kind":"purchase","planned":false,"acquired":true,"shares":31079,"price":10.53,"value":327261.87,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.445 to $10.7975, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4078922,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744255,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":23124,"price":11.79,"value":272631.96,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.5007 to $12.00, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4047843,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1744254,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-14T00:00:04.000Z","date":"2023-11-08","kind":"purchase","planned":false,"acquired":true,"shares":69127,"price":10.78,"value":745189.06,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.4891, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":4024719,"source":{"system":"sec-edgar","filing":"0001062993-23-020712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020712/form4.xml","form_type":"4"}},{"id":1747753,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-07","kind":"purchase","planned":false,"acquired":true,"shares":30192,"price":11.5,"value":347208.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3955592,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747752,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-06","kind":"purchase","planned":false,"acquired":true,"shares":43082,"price":11.55,"value":497597.1,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3925400,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1747751,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-07T23:59:41.000Z","date":"2023-11-03","kind":"purchase","planned":false,"acquired":true,"shares":22420,"price":11.38,"value":255139.6,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,955,592 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3882318,"source":{"system":"sec-edgar","filing":"0001062993-23-020279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323020279/form4.xml","form_type":"4"}},{"id":1771636,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-29","kind":"purchase","planned":false,"acquired":true,"shares":34560,"price":13.98,"value":483148.8,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.48 to $14.11, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3859898,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771635,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":25110,"price":13.69,"value":343755.9,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $13.34 to $14.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3825338,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1771634,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-29T22:53:23.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16841,"price":13.06,"value":219943.46,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $12.34 to $13.33, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,859,898 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3800228,"source":{"system":"sec-edgar","filing":"0001062993-23-018632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018632/form4.xml","form_type":"4"}},{"id":1772679,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-27","kind":"purchase","planned":false,"acquired":true,"shares":24504,"price":12.31,"value":301644.24,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.94 to $12.68, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3783387,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1772678,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-28T00:18:52.000Z","date":"2023-09-26","kind":"purchase","planned":false,"acquired":true,"shares":34000,"price":11.73,"value":398820.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.32 to $12.04, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Beneficial ownership consists of 3,783,387 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3758883,"source":{"system":"sec-edgar","filing":"0001062993-23-018547","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018547/form4.xml","form_type":"4"}},{"id":1774052,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":29967,"price":11.65,"value":349115.55,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $11.50 to $12.14, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3724883,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774051,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":30773,"price":10.8,"value":332348.4,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.49, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3694916,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1774050,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":1,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":2,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":3,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":4,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":5,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":6,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-26T01:38:12.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":11.14,"value":445600.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $10.50 to $11.48, inclusive.  The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Beneficial ownership consists of 3,724,883 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023."}],"balance_after":3664143,"source":{"system":"sec-edgar","filing":"0001062993-23-018469","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000106299323018469/form4.xml","form_type":"4"}},{"id":1776339,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2124143},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776338,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6576400},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776337,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6895021},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776336,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1144973},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776335,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":false,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":684167},"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776334,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":17,"value":25500000.0,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":3624143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776333,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":2124143,"ownership":{"direct":false,"nature":"By ARCH Venture Fund XII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":2124143,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776332,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6576400,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":11886758,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776331,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":6895021,"ownership":{"direct":false,"nature":"By ARCH Venture Fund X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP.  Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any."}],"balance_after":12205379,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776330,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":1144973,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VIII Overage, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":1144973,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1776329,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":32128,"kind":"organization","name":"ARCH Venture Partners X, LLC","position":1,"cik":"0001769012","reported_name":"ARCH Venture Partners X, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50020,"kind":"organization","name":"ARCH Venture Partners XII, LLC","position":2,"cik":"0001979548","reported_name":"ARCH Venture Partners XII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50021,"kind":"organization","name":"ARCH Venture Partners XII, L.P.","position":3,"cik":"0001979765","reported_name":"ARCH Venture Partners XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50022,"kind":"organization","name":"ARCH Venture Fund XII, L.P.","position":4,"cik":"0001906837","reported_name":"ARCH Venture Fund XII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":5,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32071,"kind":"person","name":"GILLIS STEVEN","position":6,"cik":"0001229592","reported_name":"GILLIS STEVEN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32074,"kind":"person","name":"NELSEN ROBERT","position":7,"cik":"0001219042","reported_name":"NELSEN ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32073,"kind":"person","name":"BYBEE CLINTON","position":8,"cik":"0001219043","reported_name":"BYBEE CLINTON","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-20T10:16:19.000Z","date":"2023-09-19","kind":"exercise","planned":false,"acquired":true,"shares":684167,"ownership":{"direct":false,"nature":"By ARCH Venture Fund VII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."}],"balance_after":684167,"source":{"system":"sec-edgar","filing":"0000899243-23-019274","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000089924323019274/doc4.xml","form_type":"4"}},{"id":1810980,"issuer":{"id":110669,"kind":"organization","name":"DA32 Life Science Tech Acquisition Corp.","symbol":"DALS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-10T20:28:16.000Z","date":"2023-07-28","kind":"other","planned":false,"acquired":false,"shares":1600000,"ownership":{"direct":false,"nature":"Through ARCH Venture Fund XI, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2023, the Issuer redeemed all of its outstanding shares of Class A common stock that were publicly traded for a redemption price of approximately $10.31 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"DA32 Sponsor LLC (\"Sponsor\") owns 650,000 shares of Class A common stock purchased in a private placement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As the sole general partner of ARCH Venture Fund XI, L.P. (\"AVF\"), ARCH Venture Partners XI, L.P. (\"AVP LP\") may be deemed to beneficially own the securities owned directly by AVF. As the sole general partner of AVP LP, ARCH Venture Partners XI, LLC (\"AVP LLC\") may be deemed to beneficially own securities owned directly by AVF. As a member of the investment committee of AVP LLC,  Keith Crandell may be deemed to beneficially own securities owned directly by AVF. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-23-016234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863294/000106299323016234/form4.xml","form_type":"4"}},{"id":1851724,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (option to buy)","published_at":"2023-06-16T21:52:26.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 15, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":12076,"derivative":{"exercise_price":8.68,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":12076},"source":{"system":"sec-edgar","filing":"0001562180-23-005309","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023005309/primarydocument.xml","form_type":"4"}},{"id":1851723,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-16T21:52:26.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":7777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs become fully vested on June 15, 2024 or the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs become fully vested on June 15, 2024 or the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date."}],"balance_after":7777,"derivative":{"underlying":"Common Stock","underlying_shares":7777},"source":{"system":"sec-edgar","filing":"0001562180-23-005309","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023005309/primarydocument.xml","form_type":"4"}},{"id":1851722,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-16T21:52:26.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":false,"shares":4771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs became fully vested on June 14, 2023, the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs became fully vested on June 14, 2023, the day prior to the 2023 Annual Meeting of the Stockholders of 908 Devices Inc.  The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4771},"source":{"system":"sec-edgar","filing":"0001562180-23-005309","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023005309/primarydocument.xml","form_type":"4"}},{"id":1851721,"issuer":{"id":5564,"kind":"organization","name":"908 Devices Inc.","symbol":"MASS"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:52:26.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":true,"shares":4771,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date."}],"balance_after":6150,"source":{"system":"sec-edgar","filing":"0001562180-23-005309","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023005309/primarydocument.xml","form_type":"4"}},{"id":1927305,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T22:23:24.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":1170,"price":11.16,"value":13057.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Closing price of the Company's common stock on the Nasdaq Global Market on April 3, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,083 restricted stock units."}],"balance_after":131236,"source":{"system":"sec-edgar","filing":"0001562180-23-003402","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023003402/primarydocument.xml","form_type":"4"}},{"id":2024499,"issuer":{"id":3619,"kind":"organization","name":"Twist Bioscience Corp","symbol":"TWST"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T23:08:46.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":8212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date."}],"balance_after":12189,"source":{"system":"sec-edgar","filing":"0001214659-23-001899","document":"marketforms-59384.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000121465923001899/marketforms-59384.xml","form_type":"4"}},{"id":2066356,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":32072,"kind":"person","name":"CRANDELL KEITH","position":1,"cik":"0001219039","reported_name":"CRANDELL KEITH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T21:03:56.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":12124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents non-qualified stock option to purchase 12,124 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy."}],"balance_after":12124,"derivative":{"exercise_price":12.86,"exercise_date":"2023-12-31","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":12124},"source":{"system":"sec-edgar","filing":"0001562180-23-000101","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219039/000156218023000101/primarydocument.xml","form_type":"4"}}],"next_cursor":"2023-01-04T21:03:56.000000Z,2066356"}